

Heart failure with preserved ejection fraction in mice

Predictive model to study efficacy of compounds on cardiac remodeling and heart failure with preserved ejection fraction (HFpEF)

MODEL FEATURES

- C57Bl6J mice with Angiotensin II infusion (minipumps) for 21 days
- Diastolic dysfunction / HFpEF
- Left ventricle dilation and hypertrophy
- No hypertension

KEY PARAMETERS


- Cardiac function and geometry (echography)
- Invasive left ventricle function (Millar probe)
- Blood pressure measurement
- Histology, gene / protein expression, biomarkers assays

Please contact us for customized protocol

FUNCTIONAL CHARACTERIZATION

Angiotensin II (1.5mg/kg/day for 3 weeks) in C57Bl6J mice – Echocardiography 14 and 21 days after minipumps implantation (Full data package upon request)

➤ **Angiotensin II-induced cardiac hypertrophy is reversed by Irbesartan, a AT1-receptor blocker**



➤ **Angiotensin II-induced diastolic dysfunction with preserved ejection fraction is reversed by Irbesartan, a AT1-receptor blocker**

